The most recommended stories
OF THE YEAR
-
Posted in:
Cyclophosphamide: Phase II trials
Norwegian researchers have commenced phase II trials of the anti-cancer drug cyclophosphamide on ME patients.
-
Posted in:
NIH/IOM 2015 Definition (SEID)
The proposed NIH/IOM 2015 Definition (SEID) diagnostic criteria developed by the US IOM redefines CFS for clinical application.
-
Researchers have identified distinct immune changes in patients diagnosed with chronic fatigue syndrome.
The most recent stories
From AROUND THE WORLD
-
CFS-savvy doctors are out there, if thin on the ground. In many cases these practitioners offer targeted treatment protocols which may be effective in moderating your symptoms. CFS specialists may also offer a more comprehensive diagnostic panel to rule out other conditions.
-
They’re known as the ‘invisible’ ones, the severe Myalgic Encephalomyelitis (ME) patients that governments, doctors, researchers and communities refuse to acknowledge.
-
Though there are as yet no readily available, well-accepted, objective diagnostic tests for ME and CFS, work is ongoing in several key areas to develop one.
-
An Australian six-year study evaluating progressive brain changes associated with chronic fatigue syndrome (Fukuda and Canadian Consensus Criteria definitions) shows patients’ brains deteriorate at an abnormal rate.
-
As well as specific pathogen-targeted therapies, there are many additional therapies, supplements and pharmaceuticals that can be helpful in chronic fatigue syndrome.